A detailed history of Bridgefront Capital, LLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Bridgefront Capital, LLC holds 6,063 shares of BPMC stock, worth $667,233. This represents 0.23% of its overall portfolio holdings.

Number of Shares
6,063
Holding current value
$667,233
% of portfolio
0.23%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$84.1 - $120.5 $509,898 - $730,591
6,063 New
6,063 $560,000
Q3 2021

Nov 12, 2021

SELL
$80.98 - $109.47 $317,036 - $428,575
-3,915 Closed
0 $0
Q2 2021

Aug 12, 2021

BUY
$82.78 - $101.0 $324,083 - $395,415
3,915 New
3,915 $344,000
Q1 2021

May 17, 2021

SELL
$90.71 - $108.28 $315,307 - $376,381
-3,476 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$92.08 - $124.48 $320,070 - $432,692
3,476 New
3,476 $390,000

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $6.57B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Bridgefront Capital, LLC Portfolio

Follow Bridgefront Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgefront Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridgefront Capital, LLC with notifications on news.